{
  "id": "5c6b810e7c78d6947100002e",
  "type": "factoid",
  "question": "Cerliponase alfa is apprived for treatment of which disease?",
  "ideal_answer": "Cerliponase alfa is a recombinant human tripeptidyl peptidase-1 (TPP1) approved for use in patients with neuronal ceroid lipofuscinosis type 2 (CLN2), a paediatric neurodegenerative disease caused by a deficiency in TPP1.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
    "http://www.ncbi.nlm.nih.gov/pubmed/30205177",
    "http://www.ncbi.nlm.nih.gov/pubmed/28890641",
    "http://www.ncbi.nlm.nih.gov/pubmed/29688815"
  ],
  "snippets": [
    {
      "text": "Study of Intraventricular Cerliponase Alfa for CLN2 Disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND: Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: Intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30205177",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Treatment with intracerebroventricular (ICV)-delivered cerliponase alfa enzyme replacement therapy (ERT) in a Phase 1/2 study of 24 subjects with CLN2 disease resulted in a meaningful preservation of motor and language (ML) function and was well tolerated. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30205177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cerliponase alfa (Brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (TPP1) being developed by BioMarin Pharmaceutical Inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (CLN2), a paediatric neurodegenerative disease caused by a deficiency in TPP1. CLN2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. This article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the USA for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with CLN2, and subsequent approval in the EU for CLN2 in all ages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the USA for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with CLN2, and subsequent approval in the EU for CLN2 in all ages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cerliponase Alfa: First Global Approval.Cerliponase alfa (Brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (TPP1) being developed by BioMarin Pharmaceutical Inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (CLN2), a paediatric neurodegenerative disease caused by a deficiency in TPP1. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Pharmaceutical Approval Update.Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; valbenazine (Ingrezza), the first approval for tardive dyskinesia; and cerliponase alpha (Brineura) for late infantile neuronal ceroid lipofuscinosis type-2 disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28890641",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Study of Intraventricular Cerliponase Alfa for CLN2 Disease.Intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CLN2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Cerliponase alfa (Brineura\u2122) is a recombinant human tripeptidyl peptidase-1 (TPP1) being developed by BioMarin Pharmaceutical Inc. for use in patients with neuronal ceroid lipofuscinosis type 2 (CLN2), a paediatric neurodegenerative disease caused by a deficiency in TPP1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CLN2 is characterised by progressive impairment of motor function, language deficiencies, seizures, ataxia, blindness and early death, and intracerebroventricular infusion of cerliponase alfa has been shown to reduce the progression of functional decline.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the USA for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with CLN2, and subsequent approval in the EU for CLN2 in all ages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment with intracerebroventricular (ICV)-delivered cerliponase alfa enzyme replacement therapy (ERT) in a Phase 1/2 study of 24 subjects with CLN2 disease resulted in a meaningful preservation of motor and language (ML) function and was well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30205177",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nRecombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nIntraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS Intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of cerliponase alfa leading to its first global approval in the USA for the treatment of motor function loss in paediatric patients \u22653\u00a0years of age with CLN2, and subsequent approval in the EU for CLN2 in all ages.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28589525",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>BACKGROUND</b>: Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.<br><b>METHODS</b>: In a multicenter, open-label study, we evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in children with CLN2 disease who were between the ages of 3 and 16 years.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2 patients, infections developed in the intraventricular device that was used to administer the infusion, which required antibiotic treatment and device replacement.<br><b>CONCLUSIONS</b>: Intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; valbenazine (Ingrezza), the first approval for tardive dyskinesia; and cerliponase alpha (Brineura) for late infantile neuronal ceroid lipofuscinosis type-2 disease.<br>",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28890641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recombinant human tripeptidyl peptidase 1 (cerliponase alfa) is an enzyme-replacement therapy that has been developed to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, a rare lysosomal disorder that causes progressive dementia in children.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sarilumab (Kevzara) for moderately to severely active rheumatoid arthritis; valbenazine (Ingrezza), the first approval for tardive dyskinesia; and cerliponase alpha (Brineura) for late infantile neuronal ceroid lipofuscinosis type-2 disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28890641",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29688815",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "neuronal ceroid lipofuscinosis type 2"
}